Cryptococcus neoformans infections: aspartyl protease potential to improve outcome in susceptible hosts
mBio · 2024
DOI: 10.1128/mbio.02733-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Frédérique Vernel-Pauillac und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institut Pasteur, Université Paris Cité, CNRS, Molecular Mycology Unit, UMR 2000, Paris, France. Hauptthemen laut MEDLINE: Cryptococcus neoformans, Cryptococcosis, Aspartic Acid Proteases, Antibodies, Fungal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institut Pasteur, Labex IBEID, Merieux Foundation.
Abstract (Originalsprache)
Though a confined or a broad population is exposed respectively to endemic or pandemic infections, in the same environment, some individuals resist the development of infections. The attributed reason is the inheritance of a set of immune system genes that can efficiently deal with the pathogens. In this study, we show how outbred mice differentially respond to Cryptococcus neoformans, a fungal pathogen, and the mechanism through which the surviving mice mount a protective immune defense. We identified that those mice developing antibodies specifically against Pep1p, an aspartic protease secreted by C. neoformans , had significantly improved survival. Vaccination (either prophylactic or therapeutic) with a recombinant Pep1p significantly increased the survival of the mice by decreasing the fungal load and stimulating a protective immune response. Passive immunization of C. neoformans- infected mice with monoclonal antibodies developed against Pep1p also improves the survival of the mice by increasing phagocytosis of C. neoformans and decreasing the multiplication of this fungus. Together, these data demonstrate the prophylactic and therapeutic potentials of the C. neoformans antigenic protein Pep1p or Pep1p-specific antibodies against this fungal infection. Also, this study suggests that the immunological interaction and thereby the responses developed against a pathogen guide the hosts to behave differentially against microbial pathogenicity. IMPORTANCE Vaccination and immunotherapies against fungal pathogens still remain a challenge. Here, we show using an in vivo model based on outbred mice that development of antibodies against Pep1p, an antigenic protein of the fungal pathogen Cryptococcus neoformans , confers resistance to this fungal infection. In support of this observation, prophylactic or therapeutic immunization of the mice with recombinant Pep1p could improve their survival when infected with a lethal dose of C. neoformans . Moreover, passive therapy with monoclonal anti-Pep1p antibodies also enhanced survival of the mice from C. neoformans infection. The associated antifungal mechanisms were mounting of a protective immune response and the development of fungal specific antibodies that decrease the fungal burden due to an increase in their phagocytosis and/or inhibit the fungal multiplication. Together, our study demonstrates (a) the mode of host–fungal interaction and the immune response developed thereby play a crucial role in developing resistance against C. neoformans ; (b) Pep1p, an aspartic protease as well as an antigenic protein secreted by C. neoformans , can be exploited for vaccination (both prophylactic and therapeutic) or immunotherapy to improve the host defense during this fungal infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut Pasteur, Université Paris Cité, CNRS, Molecular Mycology Unit, UMR 2000, Paris, France.
- Institut Pasteur, Université Paris Cité, CNRS UAR 2024, Mass Spectrometry for Biology Unit, Proteomics platform, Paris, France.
- Institut Pasteur, Human Histopathology and Animal Models Unit, Paris, France.
ORCID-Profile: Vishukumar Aimanianda, Françoise Dromer
Förderung
- Institut Pasteur
- Labex IBEID
- Merieux Foundation
Zitieren
APA
Vernel-Pauillac, F., Laurent-Winter, C., Fiette, L., Janbon, G., Aimanianda, V., & Dromer, F. (2024). Cryptococcus neoformans infections: aspartyl protease potential to improve outcome in susceptible hosts. mBio. https://doi.org/10.1128/mbio.02733-24
Vancouver
Vernel-Pauillac F, Laurent-Winter C, Fiette L, Janbon G, Aimanianda V, Dromer F. Cryptococcus neoformans infections: aspartyl protease potential to improve outcome in susceptible hosts. mBio. 2024. doi:10.1128/mbio.02733-24
BibTeX
@article{VernelPauillac2024,
author = {Vernel-Pauillac, Frédérique and Laurent-Winter, Christine and Fiette, Laurence and Janbon, Guilhem and Aimanianda, Vishukumar and Dromer, Françoise},
title = {Cryptococcus neoformans infections: aspartyl protease potential to improve outcome in susceptible hosts},
journal = {mBio},
year = {2024},
doi = {10.1128/mbio.02733-24}
}
EUVIMED